Celularity Inc. — Form 8-K Summary
Event date: September 29, 2026. This filing reports a board appointment and related director resignation; it does not report quarterly or annual financial results.
Business and governance context
- The Board appointed Naveen Jain as a director. His term begins after the applicable waiting period following the filing and mailing of an Information Statement under Section 14(f) and Rule 14f-1.
- Mr. Jain was designated under board appointment rights granted to certain investors in connection with Celularity’s September 2026 financing, previously disclosed in a September 28, 2026 Form 8-K.
- Diane Parks will resign from the Board effective when Mr. Jain’s appointment takes effect. The company states her resignation was not due to a disagreement with the company.
- Mr. Jain is the founder and CEO of Viome Life Sciences and has founded other technology and health-related businesses. He has not initially been appointed to a Board committee.
Financial metrics and changes
The filing provides no revenue, earnings, cash flow, margin, debt, liquidity, or other financial performance figures. It references a previously announced September 2026 financing but does not provide its terms or amounts in this filing. No financial guidance or outlook is provided.
Other disclosures
Mr. Jain will participate in the company’s standard non-employee director compensation arrangements and is expected to enter its standard director and officer indemnification agreement. The filing states that he has no reportable related-party transaction with the company and no family relationship with any director or executive officer.
Important facts for investors to verify
- The terms, amount, and other effects of the September 2026 financing in the September 28, 2026 Form 8-K.
- The effective date of Mr. Jain’s appointment and Ms. Parks’ resignation after the required Information Statement process.
- Any subsequent disclosures on Board committee assignments or director compensation.